Hester Biosciences Management Guidance Tracker

6 forward-looking guidance items tracked across 2 quarters.

Revenue

Q3 FY26PPR and Goatpox immunization programs expected from February 2026Active

Government immunization programs for PPR and goatpox (LSD) are expected to commence from February 2026, improving animal health division momentum in Q4.

Q4 FY26Animal healthcare recovery from Q1 FY27Active

Management expects animal healthcare division to recover from Q1 FY27 after tender delays in FY26.

Q4 FY26Sustain poultry quarterly revenue of ~₹65 crore with 30% marginsActive

Management aims to sustain the Q4 poultry revenue run-rate of ~₹65 crore and EBITDA margins around 30%.

Capex

Q3 FY26Remaining CWIP to be capitalized over coming monthsActive

The remaining capital work in progress (₹182 Cr) is expected to be capitalized in the coming months, adding capacity.

Margins

Q3 FY26Year-on-year margin improvement assuredTracked

Management assured year-on-year improvement in margins, though quarterly margins may vary due to product mix seasonality.

Growth

Q4 FY26Target 50:50 revenue mix between poultry and animal healthTracked

Management aims to achieve a balanced revenue mix of 50% poultry and 50% animal health over time.